Dynavax Technologies Corp
Change company Symbol lookup
Select an option...
DVAX Dynavax Technologies Corp
HOV Hovnanian Enterprises Inc
SIRI Sirius XM Holdings Inc
NVEI Nuvei Corp
JNJ Johnson & Johnson
AVGO Broadcom Inc
GILD Gilead Sciences Inc
LLY Eli Lilly and Co
ABBV Abbvie Inc
CIEN Ciena Corp
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing vaccines. The Company's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The Company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The Company is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). It is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), plague, Tdap, seasonal influenza, universal influenza, and shingles.

Price
Delayed
$11.41
Day's Change
-0.12 (-1.04%)
Bid
--
Ask
--
B/A Size
--
Day's High
11.68
Day's Low
11.31
Volume
(Light)

Today's volume of 447,338 shares is on pace to be much lighter than DVAX's 10-day average volume of 2,022,387 shares.

447,338

Display:

Providers:

UpdateCancel
6 providers
November 30, 2022
November 09, 2022
Dynavax to Present at Two Upcoming Investor Conferences

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer, Chief Executive Officer, and Kelly MacDonald, Chief Financial...(PR Newswire)

November 03, 2022
Dynavax Reports Third Quarter 2022 Financial Results

-- Q3 2022 total revenue of $167.7 million, up 55% from $108.3 million for Q3 2021 -- HEPLISAV-B(R) vaccine net product revenue of $37.5 million, up 65% from $22.7 million for Q3 2021 -- CpG 1018(R) adjuvant net product revenue of $126.3 million, up...(PR Newswire)

October 20, 2022
Dynavax to Report Third Quarter Financial Results and Host Conference Call on November 3, 2022

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter financial results on Thursday, November 3, 2022, after the U.S. financial...(PR Newswire)

October 14, 2022
Dynavax to Present at the H.C. Wainwright 3rd Annual Hepatitis B Virus Virtual Conference

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright 3rd...(PR Newswire)

October 09, 2022
September 26, 2022
September 20, 2022
Clover's COVID-19 Vaccine Candidate Receives European Union GMP Certificate

EQNX::TICKER_START (HKSE:2197),(NASDAQ:DVAX), EQNX::TICKER_END Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, today announced that Clover's...(Globe Newswire)

September 19, 2022
Clover's Universal COVID-19 Booster Vaccine Candidate Demonstrates Superior Neutralization of Omicron BA.5 Compared to Inactivated Vaccine

EQNX::TICKER_START (HKSE:2197),(NASDAQ:DVAX), EQNX::TICKER_END -- 5-fold higher neutralizing antibodies against dominant Omicron BA.5 in participants who received SCB-2019 (CpG 1018/Alum) as a heterologous third dose after two doses of inactivated...(Globe Newswire)

September 12, 2022
Dynavax Announces First Participant Dosed in a Phase 2 Clinical Trial Evaluating an Adjuvanted Plague Vaccine

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, in collaboration with the U.S. Department of Defense's (DOD) Joint Program Executive Office for...(PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.